Pfizer Settles Lipitor Battles With Ranbaxy

Law360, New York (June 18, 2008, 12:00 AM EDT) -- Pfizer Inc. has reached an agreement with generics maker Ranbaxy Laboratories Ltd. to settle most of the worldwide patent litigation between the two companies over the blockbuster cholesterol-reducing treatment Lipitor.

Under the settlement, Ranbaxy will be able to sell generic versions of Lipitor and Caduet starting Nov. 20, 2011. Caduet is a combination of Lipitor and a high blood pressure medication called Norvasc, another Pfizer product.

Lipitor is the world's most prescribed drug, with worldwide sales in 2007 of $12.7 billion. The largest market for Lipitor...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.